Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nissan Chemical Corporation

https://www.nissanchem.co.jp/eng/

Latest From Nissan Chemical Corporation

Deal Watch: Merck KGaA Enhances Cell/Gene Therapy Capabilities With Mirus Takeout

Plus deals involving Immunis/Toray, AstraZeneca/Nona, Swixx/Biopas, Deimos/G1, Serum Institute of India/IntegriMedical/ImmunityBio plus tech transfer agreements and deals in brief.

Deal Watch Business Strategies

Asia Deal Watch: Ono Calls On PRISM BioLab’s Capabilities

Plus transactions involving Nissan Chemical/Sanwa Kagaku, Memel/Therabest, Chugai/Alnylam, Takeda/Kumquat, Nxera/Handok, 3SBio/CStone and deals in brief.

Deal Watch Business Strategies

Scrip Asks...What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering

Biotech entrepreneurs tend to be an optimistic group, and there were many pockets of hope for 2024. However, the consensus remains that depressed valuations and paucity of fresh funds will continue to pose a challenge for the sector, and companies will need to prioritize carefully and work even harder to demonstrate and create value.

Scrip Asks Financing

Scrip Asks...What Does 2023 Hold For Biopharma? Part 1: The Funding Environment

With valuations down and borrowing costs up, many industry insiders are expecting Darwinian scenes in biotech this year. Survival of the fittest is the order of the day: companies with riskier, less commercially defined propositions will struggle, while platform companies with multiple shots on strong goals will increasingly find favor in a more risk-averse environment.

Scrip Asks Financing
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Dainippon Jinzo Hiryo
    • Dow AgroSciences Inc.
    • Monsanto Co., Ltd.
    • Nissan Chemical America Corporation
    • Nissan Chemical Industries, Ltd.
    • Thin Materials GmbH (Germany)
    • Tokyo Jinzo Hiryo
UsernamePublicRestriction

Register